Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.60 |
| ▸ | CDC7 | O00311 | 7/20 | 0.57 |
| ▸ | DBF4 | Q9UBU7 | 7/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | GCGR | P47871 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11287147 | 0.92 | PTGS2 (0.74) | PTGS2ALOX5PTGDR2 | |
| SCHEMBL11456658 | 0.91 | CDC7 (0.67) | PTGS2CDC7DBF4CCNE1CDK2 | |
| SCHEMBL6276676 | 0.85 | PTGS2 (0.64) | PTGS2ALOX5CDC7DBF4MAPK14 | |
| SCHEMBL6505614 | 0.83 | PTGS2 (0.66) | PTGS2ALOX5MAPK14MAPK13GCGR | |
| SCHEMBL6276678 | 0.83 | PTGS2 (0.62) | PTGS2ALOX5MAPK14MAPK10MAPK13 | |
| SCHEMBL7832748 | 0.83 | PTGS2 (0.66) | PTGS2ALOX5MAPK14MAPK13GCGR | |
| SCHEMBL9768642 | 0.82 | ALDH1A1 (0.62) | PTGS2ALOX5CDC7DBF4CCNE1 | |
| SCHEMBL7840831 | 0.81 | PTGS2 (0.78) | PTGS2ALOX5MAPK14 | |
| SCHEMBL7841916 | 0.81 | PTGS2 (1.00) | PTGS2MAPK14 | |
| SCHEMBL6276579 | 0.81 | PTGS2 (0.63) | PTGS2ALOX5CDC7DBF4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | claimed |
| US-6962933-B1 | Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-08 | — | — | US | disclosed |
| US-20050080113-A1 | Medicinal compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-14 | — | — | US | disclosed |
| US-20040097555-A1 | Concomitant drugs | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1402900-A1 | MEDICINAL COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1354603-A1 | CONCOMITANT DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| EP-1205478-A1 | p38MAP KINASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2002-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080113-A1 | Medicinal compositions | TNF, TRAF6, MMP8 | PTGS2 57/4885ALOX5 586/4885CDC7 750/4885 |
| US-20040097555-A1 | Concomitant drugs | TNF, CHUK, CNKSR1 | PTGS2 109/4885ALOX5 1251/4885CDC7 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.